(Z)-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one | 181765-58-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (Z)-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one
• 英文别名: (Z)-5-naphthalen-1-ylmethylene-2-thioxo-4-thiazolidinone；5-[(1-naphthyl)methylene]-2-thioxo-4-thiazolidinone；5-naphthalen-1-ylmethylene-2-thioxothiazolidin-4-one；(5Z)-5-(naphthalen-1-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one
• CAS: 181765-58-2
• 化学式: C₁₄H₉NOS₂
• 分子量: 271.364
• InChiKey: KHWBBJGNDBRXEW-WQLSENKSSA-N

物化性质

• 熔点：
  229-232 °C
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one 、 sodium hydroxide 、 乙醇 生成 β-1-naphthyl-α-mercaptoacrylic acid
  参考文献：
  名称：

  AGER, IAN R.;BARNES, ALAN C.;DANSWAN, GEOFFREY W.;HAIRSINE, PETER W.;KAY,+, J. MED. CHEM., 31,(1988) N 6, 1098-1115

  摘要：

  DOI：
• 作为产物：
  描述：

  罗丹宁 、 1-萘甲醛 在 溶剂黄146 、 三乙胺 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 以100%的产率得到(Z)-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one
  参考文献：
  名称：

  Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2

  摘要：

  The identification, synthesis and evaluation of a series of rhodanine and thiazolidin-2,4-dione derivatives as selective inhibitors of human arylamine N-acetyltransferase 1 and mouse arylamine N-acetyltransferase 2 is described. The most potent inhibitors identified have submicromolar activity and inhibit both the recombinant proteins and human NAT1 in ZR-75 cell lysates in a competitive manner. H-1 NMR studies on purified mouse Nat2 demonstrate that the inhibitors bind within the putative active site of the enzyme. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.11.032

文献信息

• Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
  申请人：——

  公开号：US20030229120A1

  公开（公告）日：2003-12-11

  Novel ligands for the HisB10 Zn 2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

  揭示了能够延长胰岛素制剂作用的R-态胰岛素六聚体的HisB10 Zn2+位点的新配体。
• Stabilised insulin compositions
  申请人：Kaarsholm Christian Niels

  公开号：US20050065066A1

  公开（公告）日：2005-03-24

  The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the His B10 Zn 2+ sites of the R-state insulin hexamer. The resulting preparations have improved physical and chemical stability.

  本发明提供了包含胰岛素和新型配体的药物组合物，用于R-态胰岛素六聚体的His B10 Zn2+位点。由此制备的药物具有改善的物理和化学稳定性。
• [EN] PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN<br/>[FR] PREPARATIONS PHARMACEUTIQUES CONTENANT DE L'INSULINE STABILISEE D'UN POINT DE VUE ACIDE
  申请人：NOVO NORDISK AS

  公开号：WO2004080480A1

  公开（公告）日：2004-09-23

  Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

  揭示了能够延长胰岛素制剂作用的R态胰岛素六聚体的HisB10 Zn2+位点的新配体。
• CHARGE CONTROLLING AGENT AND TONER USING SAME
  申请人：Yasumura Masateru

  公开号：US20120315576A1

  公开（公告）日：2012-12-13

  The present invention provides a charge control agent containing, as an active substance(s), one or two or more rhodanine compounds represented by the following formula (1). where R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms which may have a substituent, a substituted or unsubstituted heterocyclic group, etc.; R3 to R7, which may be identical to or different from each other, represent a hydrogen atom, a linear or branched alkyl group having 1 to 10 carbon atoms which may have a substituent, a linear or branched alkyloxy group having 1 to 20 carbon atoms which may have a substituent, etc., and may be joined to each other to form a ring; and V, W, X, Y and Z represent a carbon atom or a nitrogen atom, and 0 to 3 of any of V, W, X, Y and Z are nitrogen atoms which do not have the substituents of R3 to R7.

  本发明提供了一种包含以下式（1）所表示的一种或两种或更多罗丹宁化合物作为活性物质的电荷控制剂。其中R1代表氢原子等；R2代表氢原子、具有1至8个碳原子的线性或支链烷基基团，该基团可能具有取代基，取代或未取代的杂环基团等；R3至R7（它们可以相同也可以不同）代表氢原子、具有1至10个碳原子的线性或支链烷基基团，该基团可能具有取代基，具有1至20个碳原子的线性或支链烷氧基基团，该基团可能具有取代基等，并且它们可以相互连接形成环；V、W、X、Y和Z代表碳原子或氮原子，V、W、X、Y和Z中的任意0至3个是不具有R3至R7的取代基的氮原子。
• Pharmaceutical preparations comprising acid-stabilised insulin
  申请人：Ostergaard Soren

  公开号：US20060069013A1

  公开（公告）日：2006-03-30

  Novel ligands for the HisB10 Zn 2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.

  本发明揭示了能够延长胰岛素制剂作用的R态胰岛素六聚体的HisB10 Zn2+位点的新型配体。